Kronos Bio, Inc. (KRON)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Norbert W. Bischofberger
Employees:
100
1300 S. EL CAMINO REAL, SUITE 300, SAN MATEO, CA 94402
212-871-7920

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. Its lead product candidate is entospletinib (ENTO), an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company was incorporated in 2017 and is headquartered in San Mateo, California.

Data derived from most recent annual or quarterly report
Market Cap 89.327 Million Shares Outstanding57.63 Million Avg 30-day Volume 252.087 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.57
Price to Revenue68.3333 Debt to Equity0.0 EBITDA-129.268 Million
Price to Book Value0.3698 Operating Margin-10585.0123 Enterprise Value-157.852 Million
Current Ratio9.194 EPS Growth0.256 Quick Ratio8.961
1 Yr BETA 2.0568 52-week High/Low 5.74 / 1.2 Profit Margin-10088.3702
Operating Cash Flow Growth40.0466 Altman Z-Score-1.8688 Free Cash Flow to Firm -73.15 Million
Earnings Report2023-08-03

Are you looking for this stock instead?

View SEC Filings from KRON instead.

View recent insider trading info

Kronos Bio, Inc. YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding KRON (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding KRON

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-04-24 by DANSEY ROGER D
  • 3: filed on 2023-04-24 by DANSEY ROGER D
  • 4: filed on 2023-04-11 by STULTZ KATHERINE V
  • 3: filed on 2023-04-11 by STULTZ KATHERINE V
  • 4: filed on 2023-02-17 by DINSMORE CHRISTOPHER
  • 4: filed on 2023-02-17 by KOSACZ BARBARA
  • 4: filed on 2023-02-17 by DIMARTINO JORGE
  • 4: filed on 2023-02-17 by AL-WAKEEL YASIR B.
  • 4: filed on 2023-02-17 by BISCHOFBERGER NORBERT W
  • 4: filed on 2022-12-14 by DIMARTINO JORGE

    • Events (8k)

  • 8-K/A: filed on 2023-05-30:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K/A: filed on 2023-05-30:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2023-05-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-04-24:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2023-04-11:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2023-03-27:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K/A: filed on 2023-03-27:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2023-03-15:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-26:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2023-01-09:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 7.01: Regulation FD Disclosure

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    DANSEY ROGER D

    • Director
    		 0 2023-04-20 2

    STULTZ KATHERINE V

    • Director
    		 0 2023-04-10 2

    AL-WAKEEL YASIR B. CHIEF FINANCIAL OFFICER

    • Officer
    		 355,719 2023-02-24 3

    DIMARTINO JORGE CHIEF MEDICAL OFFICER & VP

    • Officer
    		 355,440 2023-02-24 4

    DINSMORE CHRISTOPHER CHIEF SCIENTIFIC OFFICER

    • Officer
    		 285,001 2023-02-24 4

    BISCHOFBERGER NORBERT W PRESIDENT & CEO

    • Officer
    • Director
    		 5,443,853 2023-02-15 1

    KOSACZ BARBARA COO & GENERAL COUNSEL

    • Officer
    		 939,642 2023-02-15 2

    TANEN DAVID M

    • Director
    		 34,000 2022-06-22 1

    KAZAM JOSHUA A

    • Director
    		 34,000 2022-06-22 1

    BELLDEGRUN ARIE

    • Director
    		 34,000 2022-06-22 1

    YANG TAIYIN

    • Director
    		 28,333 2022-06-22 1

    STAMPACCHIA OTELLO

    • Director
    		 34,000 2022-06-22 1

    RIDLOFF ELENA

    • Director
    		 34,000 2022-06-22 1

    BLUNT ROSHAWN A.

    • Director
    		 34,000 2022-06-22 1

    DE BACKER MARIANNE

    • Director
    		 31,083 2022-06-22 1

    LOVEN JAKOB

    • Director
    		 1,301,537 2021-04-16 0

    MARTIN JOHN C

    • Director
    		 1,952,364 2020-10-14 0

    OMEGA FUND V, L.P.

    OMEGA FUND V GP, L.P.

    OMEGA FUND V GP MANAGER, LTD.

    PASTER ANNE-MARI

    NESSI CLAUDIO

    STAMPACCHIA OTELLO

    • Director
    • 10% Owner
    		 No longer subject to file 2020-10-14 0

    BISCHOFBERGER NORBERT W. & INGER A. REVOCABLE INTER VIVOS TRUST

    • 10% Owner
    		 No longer subject to file 2020-10-14 0

    BELLDEGRUN REBECKA

    • Director
    		 679,575 2020-10-14 0

    LACY PAUL A PRESIDENT

    • Officer
    		 71,392 2007-04-10 0

    AIN MARK S EXECUTIVE CHAIRMAN

    • Officer
    • Director
    		 254,916 2007-04-03 0

    JULIEN MARK V CHIEF FINANCIAL OFFICER

    • Officer
    		 7,875 2007-03-23 0

    DEMARTINO JOSEPH SR. VP, N.A. FIELD OPERATIONS

    • Officer
    		 35,519 2007-03-22 0

    GEORGE PETER SR. VP, ENGINEERING AND CTO

    • Officer
    		 74,722 2007-03-20 0

    KIZIELEWICZ JAMES SR. VP, CORPORATE STRATEGY

    • Officer
    		 38,354 2007-03-16 0

    BUSSELL LLOYD B VICE PRESIDENT, MANUFACTURING

    • Officer
    		 20,751 2007-02-05 0

    AIN ARON J CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 371,732 2006-04-17 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    DANSEY ROGER D - Director

    		2023-04-24 16:22:40 -0400 2023-04-20 A 68,000 a 68,000 direct

    STULTZ KATHERINE V - Director

    		2023-04-11 16:40:51 -0400 2023-04-10 A 68,000 a 68,000 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    KRONOS BIO INC KRON 2023-05-31 22:15:04 UTC 2.5079 2.5521 450000
    KRONOS BIO INC KRON 2023-05-31 21:45:04 UTC 2.5079 2.5521 450000
    KRONOS BIO INC KRON 2023-05-31 21:15:03 UTC 2.5079 2.5521 450000
    KRONOS BIO INC KRON 2023-05-31 20:45:04 UTC 2.5079 2.5521 450000
    KRONOS BIO INC KRON 2023-05-31 20:15:06 UTC 2.5065 2.5535 450000
    KRONOS BIO INC KRON 2023-05-31 19:45:04 UTC 2.5065 2.5535 450000
    KRONOS BIO INC KRON 2023-05-31 19:15:21 UTC 2.5065 2.5535 450000
    KRONOS BIO INC KRON 2023-05-31 18:45:03 UTC 2.5065 2.5535 450000
    KRONOS BIO INC KRON 2023-05-31 18:15:04 UTC 2.5065 2.5535 450000
    KRONOS BIO INC KRON 2023-05-31 17:45:03 UTC 2.5065 2.5535 450000
    KRONOS BIO INC KRON 2023-05-31 17:15:05 UTC 2.5065 2.5535 450000
    KRONOS BIO INC KRON 2023-05-31 16:45:04 UTC 2.5062 2.5638 450000
    KRONOS BIO INC KRON 2023-05-31 16:15:04 UTC 2.5062 2.5638 450000
    KRONOS BIO INC KRON 2023-05-31 15:45:03 UTC 2.5062 2.5638 450000
    KRONOS BIO INC KRON 2023-05-31 15:15:04 UTC 2.5062 2.5638 450000
    KRONOS BIO INC KRON 2023-05-31 14:45:04 UTC 2.5062 2.5638 450000
    KRONOS BIO INC KRON 2023-05-31 14:15:03 UTC 2.5062 2.5638 450000
    KRONOS BIO INC KRON 2023-05-31 13:45:04 UTC 2.4951 2.5749 450000
    KRONOS BIO INC KRON 2023-05-31 13:15:04 UTC 2.4951 2.5749 450000
    KRONOS BIO INC KRON 2023-05-31 12:45:04 UTC 2.4951 2.5749 450000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    RUSSELL INVESTMENT FUNDS- U.S. Small Cap Equity Fund KRON -1000.0 shares, $-1460.0 2023-03-31 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments